Sidley represented Vivo Capital and Novo Holdings A/S as lead investors in the US$200 million Series A and Crossover round financing for Esco Lifesciences (Esco), with participation from other institutional investors.
Vivo Capital is a leading global healthcare investment firm with a diverse, multi-fund investment platform in venture capital, growth equity, buyout, and public equities. Novo Holdings is a leading life science investor which provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Headquartered in Singapore, Esco provides enabling technologies, products, and services to the life sciences and healthcare industries, supporting academic research and scientific discoveries, clinical practice, as well as biopharmaceutical R&D and manufacturing.
The Sidley team was led by partner Ruchun Ji. Other team members included counsel David Kalani Lee, associate Kylie Wang, and China advisor Flora Wu.
Sidley’s Private Equity practice in Asia has shown a rapid growth in recent years. In 2021 Q1, it is ranked by Bloomberg as one of the top 10 legal advisors in Asia Pacific Private Equity League Table (by announced deal value).
Sidley provides multidisciplinary services for life sciences clients. We advise clients across the full spectrum of their business lifecycles, ranging from formation, corporate governance, and compliance operations for start-ups, to collaboration, licensing, commercialization, and filing in the business development phase, including initial public offerings, refinancings, and bond/note issuances, as well as domestic and cross-border mergers and acquisitions, asset restructuring, equity incentive plans, and privatizations.